Androgen receptor signalling pathway and possible therapeutic targets ın prostate cancer

Year 2025, Volume: 39 Issue: 1, 73 - 88, 12.03.2025

Fatma Seher Delek

Abstract

A kind of cancer affecting millions of men globally is prostate cancer (PCa). The way that PCa is treated is always changing because of new insights into human genetics and biological processes. A number of novel therapeutic classes have emerged in recent times, such as bone-targeted medications, poly(ADP-ribose) polymerase (PARP) inhibitors, and next-generation androgen receptor (AR) signaling inhibitors. Additionally, PSMA-targeting drugs show promise as theranostics that might enhance the precision of diagnosis and effectiveness of treatment. The outcome of prostate cancer is significantly influenced by the AR signaling pathway. This study examines novel molecules that are either now targeted or may be targeted in the AR signaling pathway, which is highly successful in the carcinogenesis of prostate cancer.

Prostate cancer, androgen receptor signaling pathway, therapeutic targets.

Keywords

Prostate cancer, androgen receptor signaling pathway, therapeutic targets.

References

• 1. IARC. Absolute numbers, Incidence, Males, in 2022, World. [cited 2024 Mar 20]; Available from: https://gco.iarc.fr/today/en/dataviz/pie?mode=cancer&sexes=1&populations=900
• 2. IARC. Absolute numbers, Incidence, Males, in 2022, Türkiye. [cited 2024 Mar 20]; Available from: https://gco.iarc.fr/today/en/dataviz/pie?mode=cancer&group_populations=1&sexes=1&populations=
• 3. International Cancer Institute. International Cancer Institute. 2022. Prostate Cancer Prevention (PDQ®)–Patient Version.
• 4. Mehralivand S, Thomas C, Puhr M, Claessens F, van de Merbel AF, Dubrovska A, et al. New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium. J Transl Med. 2024 Dec 1;22(1).
• 5. Zakari S, Ekenwaneze CC, Amadi EC, Abuhamdia A, Ogunlana OO. Unveiling the latest insights into Androgen Receptors in Prostate Cancer. International Journal of Medical Biochemistry. 2024;7(2):101–13.
• 6. Tan ME, Li J, Xu HE, Melcher K, Yong EL. Androgen receptor: Structure, role in prostate cancer and drug discovery. Vol. 36, Acta Pharmacologica Sinica. Nature Publishing Group; 2015. p. 3–23.
• 7. Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, et al. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Vol. 9, Cells. NLM (Medline); 2020.
• 8. Lonergan P, Tindall D. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011;10.
• 9. Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, Haelens A. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Vol. 6, Nuclear receptor signaling. 2008.
• 10. Deng T, Xiao Y, Dai Y, Xie L, Li X. Roles of Key Epigenetic Regulators in the Gene Transcription and Progression of Prostate Cancer. Front Mol Biosci. 2021 Dec 15;8:743376. 11. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. Vol. 99, Journal of Cellular Biochemistry. 2006. p. 333–44.
• 12. Li X, Xiong H, Mou X, Huang C, Thomas ER, Yu W, et al. Androgen receptor cofactors: A potential role in understanding prostate cancer. Biomedicine & Pharmacotherapy. 2024 Apr 1;173:116338.
• 13. Alexandrova E, Salvati A, Pecoraro G, Lamberti J, Melone V, Sellitto A, et al. Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors. Front Genet. 2022 Apr 13;13:864612.
• 14. Vatapalli R, Sagar V, Rodriguez Y, Zhao JC, Unno K, Pamarthy S, et al. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nat Commun. 2020 Dec 1;11(1).
• 15. Obinata D, Funakoshi D, Takayama K, Hara M, Niranjan B, Teng L, et al. OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer. Sci Rep. 2022 Dec 1;12(1).
• 16. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO Journal. 2011 Oct 5;30(19):3962–76.
• 17. Dong HY, Ding L, Zhou TR, Yan T, Li J, Liang C. FOXA1 in prostate cancer. Vol. 25, Asian Journal of Andrology. Wolters Kluwer Medknow Publications; 2023. p. 287–95.
• 18. Obinata D, Takayama KI, Urano T, Murata T, Kumagai J, Fujimura T, et al. Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int J Cancer. 2012 Mar 1;130(5):1021–8.
• 19. Daniels G, Li Y, Gellert LL, Zhou A, Melamed J, Wu X, et al. TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth. Endocr Relat Cancer. 2014 Feb;21(1):127–42.
• 20. Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: The role of interleukin 6 (IL-6). Vol. 113, BJU International. Blackwell Publishing Ltd; 2014. p. 986–92.
• 21. Li BH, Yan SY, Luo LS, Zeng XT, Wang YB, Wang XH. Ten interleukins and risk of prostate cancer. Front Oncol. 2023 Jan 17;13:1108633.
• 22. Culig Z. Cytokine disbalance in common human cancers. Vol. 1813, Biochimica et Biophysica Acta - Molecular Cell Research. 2011. p. 308–14.
• 23. Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene. 2010 Jun 3;29(22):3208–16.
• 24. Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci. 2020 Jun 2;21(12):4507.
• 25. Thomas-Jardin SE, Dahl H, Nawas AF, Bautista M, Delk NA. NF-κB signaling promotes castration-resistant prostate cancer initiation and progression. Pharmacol Ther. 2020 Jul 1;211:107538.